Such insights may ultimately facilitate the development of strategies to modulate the DAMP–NLRP3 axis and maintain balanced inflammasome activation, aiding in the diagnosis and treatment of autoimmune and inflammatory diseases, including pulmonary hypertension, which remains one of the most challenging conditions to diagnose and manage today. This evidence concerns the gene NLRP3 and pulmonary arterial hypertension.